Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.16 is 50% below its 5-year average of 0.31, near the high end of its 5-year range (-2.61–0.64).
As of the fiscal period ended Tuesday, June 30, 2026. 2.11% above its 12-month average of 0.15.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.16.
DEBT TO EQUITY RATIO
0.16
DEBT TO EQUITY RATIO AVG TTM
0.15
DEBT TO EQUITY RATIO AVG 3Y
0.33
DEBT TO EQUITY RATIO AVG 5Y
0.31
DEBT TO EQUITY RATIO AVG 10Y
0.20
DEBT TO EQUITY RATIO AVG 15Y
0.13
DEBT TO EQUITY RATIO AVG 20Y
0.06
CURRENT VS TTM AVG
+2.11%
CURRENT VS 3Y AVG
-52.80%
CURRENT VS 5Y AVG
-50.50%
CURRENT VS 10Y AVG
-23.12%
CURRENT VS 15Y AVG
+21.58%
CURRENT VS 20Y AVG
+153.68%
SECTOR MEDIAN · HEALTHCARE
0.12
median of 639 covered companies
CURRENT VS SECTOR MEDIAN
+29.32%
vs the sector median at left
Abeona Therapeutics Inc.
Market Cap
$288.40M
Debt to Equity Ratio
0.16
TTM Avg
0.15
3Y Avg
0.33
5Y Avg
0.31
Market Cap
$289.76M
Debt to Equity Ratio
0.05
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.50
Market Cap
$289.63M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$285.37M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$284.21M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$296.13M
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.05
5Y Avg
0.06
Market Cap
$280.29M
Debt to Equity Ratio
0.04
TTM Avg
0.11
3Y Avg
0.22
5Y Avg
0.26
Market Cap
$277.99M
Debt to Equity Ratio
0.49
TTM Avg
0.33
3Y Avg
0.29
5Y Avg
0.26
Market Cap
$300.36M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.70
5Y Avg
0.51
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $288.40M | 0.16 | 0.15 | 0.33 | 0.31 |
| Standard BioTools Inc. (LAB)vs › | $289.76M | 0.05 | 0.07 | 0.07 | 0.50 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | 0.01 | 0.01 | 0.01 | 0.01 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | 0.00 | 0.01 | 0.01 | 0.01 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | 0.02 | 0.03 | 0.04 | 0.03 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.13M | 0.04 | 0.04 | 0.05 | 0.06 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | 0.04 | 0.11 | 0.22 | 0.26 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.99M | 0.49 | 0.33 | 0.29 | 0.26 |
| Benitec Biopharma Inc. (BNTC)vs › | $300.36M | 0.00 | 0.01 | 0.70 | 0.51 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | 0.07 | 0.07 | 0.06 | 0.07 |
Debt/Equity
0.16
Current Ratio
6.63
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.16 |
| 2026-03-31 | 0.16 |
| 2025-12-31 | 0.16 |
| 2025-09-30 | 0.14 |
| 2025-06-30 | 0.15 |
| 2025-03-31 | 0.58 |
| 2024-12-31 | 0.52 |
| 2024-09-30 | 0.50 |
| 2024-06-30 | 0.32 |
| 2024-03-31 | -2.61 |
| 2023-12-31 | 0.36 |
| 2023-09-30 | 0.26 |
| 2023-06-30 | 0.64 |
| 2023-03-31 | 0.39 |
| 2022-12-31 | 0.29 |
| 2022-09-30 | 0.54 |
| 2022-06-30 | 0.42 |
| 2022-03-31 | 0.29 |
| 2021-12-31 | 0.22 |
| 2021-09-30 | 0.08 |
| 2021-06-30 | 0.10 |
| 2021-03-31 | 0.09 |
| 2020-12-31 | 0.09 |
| 2020-09-30 | 0.08 |
| 2020-06-30 | 0.08 |
| 2020-03-31 | 0.06 |
| 2019-12-31 | 0.04 |
| 2019-09-30 | 0.40 |
| 2019-06-30 | 0.36 |
| 2019-03-31 | 0.33 |
| 2018-12-31 | 0.22 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.07 |
| 2016-03-31 | 0.06 |
| 2015-12-31 | 0.06 |
| 2015-09-30 | 0.05 |
| 2015-06-30 | 0.07 |
| 2015-03-31 | 1.27 |
| 2014-12-31 | 0.91 |
| 2014-09-30 | -0.01 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 0.00 |
| 2012-09-30 | -0.06 |
| 2012-06-30 | -0.09 |
| 2012-03-31 | -0.14 |
| 2011-12-31 | -0.16 |
| 2011-09-30 | -0.23 |
| 2011-06-30 | -0.23 |
| 2011-03-31 | -0.24 |
| 2010-12-31 | -0.26 |
| 2010-09-30 | -0.18 |
| 2010-06-30 | -0.31 |
| 2010-03-31 | -0.27 |
| 2009-12-31 | -0.20 |
| 2009-09-30 | -0.35 |
| 2009-06-30 | -0.40 |
| 2009-03-31 | -0.46 |
| 2008-12-31 | -0.57 |
| 2008-09-30 | -0.78 |
| 2008-06-30 | -1.35 |
| 2008-03-31 | -3.84 |
| 2007-12-31 | 8.17 |
| 2007-09-30 | -0.98 |
| 2007-06-30 | -1.06 |
| 2007-03-31 | -1.19 |
| 2006-12-31 | -1.45 |
| 2006-09-30 | -1.24 |
| 2006-06-30 | -1.41 |
| 2006-03-31 | -1.76 |
| 2005-12-31 | -1.83 |
| 2005-09-30 | -1.25 |
| 2005-06-30 | -1.34 |
| 2005-03-31 | -1.93 |
| 2004-12-31 | -2.09 |
| 2004-09-30 | -3.70 |
| 2004-06-30 | -9.31 |
| 2004-03-31 | 14.83 |
| 2003-12-31 | -2.47 |
| 2003-09-30 | -4.07 |
| 2003-06-30 | -10.68 |
| 2003-03-31 | -7.77 |
| 2002-12-31 | 30.71 |
| 2002-09-30 | 5.33 |
